The test will be distributed by Infrawear to labs and pharmacies in the United Kingdom, France, Italy, Germany and elsewhere in the EU.
It was also just announced that Genesprint and Infrawear just made it to the semi-finals for the USD 5m XPRIZE Rapid COVID Testing competition. The test has been CE marked to the IVD Directive (98/79/EC).
Genesprint Group Ltd has been developing research and manufacturing diagnostic kits for various infectious diseases for more than three years.
The virology team has 50 years of combined rapid test development experience. It has been working on COVID-19 tests since the virus first appeared.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy